AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$ARTV

Bush Jennifer sold $57K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 8,370 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 on 2026-10-05.

Original reporting
SEC EDGAR · Bush Jennifer
Published Oct 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially.

02

Market read

A small insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing could drive the sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

COO Jennifer Bush sold 8,370 shares for $57,227, a Form 4 insider sale disclosed on 2026-10-06.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

The sale amount is small relative to holdings and market cap, so impact is limited.

Market effects

Sector

None significant for the biotech sector.

Regional

No broader regional effect.

Global

Limited to ARTV investors.

Counterpoint

What could challenge this read

The sale may be routine and not indicative of future performance.

Key entities

  • person
    Jennifer Bush

    COO, CLO, and Compliance Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min